Login to Your Account



Basilea a Takeover Candidate?

Data Monitoring Deficiencies Sink Ceftobiprole Once Again

By Jennifer Boggs


Thursday, December 31, 2009
Basilea Pharmaceutica AG's antibiotic ceftobiprole failed for the third time to clear FDA review due to data integrity issues, news that sent shares falling 15 percent but could give the Swiss company more ammunition in its ongoing arbitration process claiming damages against partner Johnson & Johnson. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription